| Document Date: 2014-10-29 21:41:38
Open Document File Size: 71,05 KBShare Result on Facebook
City Athens / San Diego / / Company ViaCyte Inc. / / Event FDA Phase / / Facility UCSD The Sanford Stem Cell Clinical Center / California Institute / / IndustryTerm implantation site / durable and retrievable encapsulation device / combination product / treatment of diabetes / diabetes treatment / therapy for diabetes / energy / / MedicalCondition potential long-term diabetes / chronic condition / juvenile diabetes / disease / diabetes-related complications / diabetes / target disease / diabetes mellitus / hypoglycemia / / MedicalTreatment drug delivery system / cell therapy / / Organization UC San Diego Sanford Stem Cell Clinical Center / Sanford Stem Cell Clinical Center / JDRF / California Institute for Regenerative Medicine / UCSD / / Person Paul Laikind / Robert Henry / / Position counsel / Principal Investigator / President and CEO / / Product VC-01 / glucagon / VC-01 combination product / / ProvinceOrState Maryland / California / Georgia / / Technology cell therapy / drug delivery system / stem cells / regenerative medicine / on developing a novel cell therapy / / URL www.viacyte.com / /
SocialTag |
ViaCyte’s VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted into First Patient San Diego, California, October 29, 2014 — ViaCyte, Inc., a privately-held regenerative medicine